In This Section

Home / About / Corporate Members / Industry Advisory Council

Industry Advisory Council

Over the past decade, ACCC leadership has invited a select group of companies to join the Industry Advisory Council (IAC). IAC companies meet with the Association's Board of Trustees twice a year to discuss current issues of interest. In addition, IAC companies and ACCC leadership work together throughout the year on specific causes of mutual concern. Typically, ACCC leadership visits each IAC member's corporate office at least once a year to discuss with the product, marketing, and governmental affairs teams their current issues of concern to cancer patients and providers.

Benefits of Membership

Industry Advisory Council members receive a variety of benefits, including recognition through the ACCC network and better visibility with the nationwide cancer care community. Join the Industry Advisory Council and you will:

  • Receive timely updates on current legislative and regulatory issues
  • Gain direct contact with key oncology decision makers
  • Gain access to a forum in which to communicate their concerns
  • Have access to experts in reimbursement, practice management, and health economics.

Members can express their ideas to the oncology community and, in turn, learn what the oncology community thinks about them and their products.

Current IAC Members

abbvie-200x80 amgen-200x80 astellas-200x80 athenex-200x80 astrazeneca-200x80 bayerpharmaceuticals-200x80 bluebirdbio-200x80 bms-200x80 deciphera-200x80 eisai-200x80 grid-epizyme-200x80 genentech-200x80 gilead-200x80 GSK-200x80 janssen-200x80 lilly-oncology-200x80 merck-200x80 Novartis-200x80 Pfizer-200x80   regeneron-200x80 Sandoz-200x80 Sanofi-200x80 tersera-200x80 teva-200x80